Health and Healthcare
Why This Hairy Cell Leukemia Treatment Could Be Big in Europe
Published:
Innate Pharma S.A. (NASDAQ: IPHA) shares jumped on Thursday after the firm announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for Lumoxiti for adult patients with relapsed or refractory hairy cell leukemia.
The EMA filing is based on the final analysis of the pivotal Phase 3 trial of Lumoxiti, presented at the 2019 American Society of Hematology annual meeting.
The data showed that 36% of the relapsed or refractory hairy cell leukemia patients achieved durable complete response. The objective response rate was at 75%. Eighty-one percent of patients with a complete response experienced eradication of minimal residual disease. In addition, there was a 61% probability that patients who achieved a complete response would maintain it after five years.
The EMA filling acceptance follows the U.S. Food and Drug Administration (FDA) approval of Lumoxiti in September 2018. Lumoxiti was previously granted Orphan Drug Designation by the FDA and EMA. AstraZeneca is the current Biologics License Application holder for Lumoxiti in the United States and is also the marketing authorization applicant for the EU filing.
Pierre Dodion, M.D., executive vice president and chief medical officer of Innate Pharma, commented:
If approved by the EMA, Lumoxiti will be the first treatment available in Europe for relapsed or refractory hairy cell leukemia patients in more than twenty years, potentially changing the standard of care for these patients. We are dedicated in addressing the unmet need in this rare form of cancer that can result in serious and life-threatening conditions, and as such, are hopeful we can bring this important medicine to patients in Europe as soon as possible.
Shares of Innate Pharma were last seen up about 27% at $8.15, in a 52-week range of $5.61 to $8.24. The consensus price target is $12.00.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
